SPARC is a key mediator of TGF‐β‐induced renal cancer metastasis
Authors:
- 11 August 2020
- journal article
- research article
- Published by Wiley in Journal of Cellular Physiology
- Vol. 236 (3) , 1926-1938
Abstract
Aberrant expression of transforming growth factor‐β1 (TGF‐β1) is associated with renal cell carcinoma (RCC) progression by inducing cancer metastasis. However, the downstream effector(s) in TGF‐β signaling pathway is not fully characterized. In the present study, the elevation of secreted protein acidic and rich in cysteine (SPARC) as a TGF‐β regulated gene in RCC was identified by applying differentially expressed gene analysis and microarray analysis, we further confirmed this result in several RCC cell lines. Clinically, the expression of these two genes is positively correlated in RCC patient specimens. Furthermore, elevated SPARC expression is found in all the subtypes of RCC and positively correlated with the RCC stage and grade. In contrast, SPARC expression is inversely correlated with overall and disease‐free survival of patients with RCC, suggesting SPARC as a potent prognostic marker of RCC patient survival. Knocking down SPARC significantly inhibits RCC cell invasion and metastasis both in vitro and in vivo. Similarly, in vitro cell invasion can be diminished by using a specific monoclonal antibody. Mechanistically, SPARC activates protein kinase B (AKT) pathway leading to elevated expression of matrix metalloproteinase‐2 that can facilitate RCC invasion. Altogether, our data support that SPARC is a critical role of TGF‐β signaling network underlying RCC progression and a potential therapeutic target as well as a prognostic marker.Keywords
Funding Information
- American Cancer Society (133186‐PF‐19‐087‐01‐CSM)
- China Scholarship Council (201508440279)
- Institut National Du Cancer (1P30 CA142543)
This publication has 44 references indexed in Scilit:
- The Epithelial-Mesenchymal Transition (EMT) Regulatory Factor SLUG (SNAI2) Is a Downstream Target of SPARC and AKT in Promoting Melanoma Cell InvasionPLOS ONE, 2012
- Losartan Slows Pancreatic Tumor Progression and Extends Survival of SPARC-Null Mice by Abrogating Aberrant TGFβ ActivationPLOS ONE, 2012
- Cancers with increasing incidence trends in the United States: 1999 through 2008CA: A Cancer Journal for Clinicians, 2012
- Sarcomatoid renal cell carcinoma is an example of epithelial–mesenchymal transitionJournal of Clinical Pathology, 2011
- Lack of host SPARC enhances vascular function and tumor spread in an orthotopic murine model of pancreatic carcinomaDisease Models & Mechanisms, 2010
- The regulation of TGFβ signal transductionDevelopment, 2009
- The Expression and Clinical Significance of TGF-β1 and MMP2 in Human Renal Clear Cell CarcinomaInternational Journal of Surgical Pathology, 2009
- TGFβ in CancerCell, 2008
- Snail is required for transforming growth factor-β-induced epithelial–mesenchymal transition by activating PI3 kinase/Akt signal pathwayBiochemical and Biophysical Research Communications, 2007
- Expression of a suicidal gene under control of the human secreted protein acidic and rich in cysteine (SPARC) promoter in tumor or stromal cells led to the inhibition of tumor cell growthMolecular Cancer Therapeutics, 2006